About 60,000 people in several countries have received Chinese experimental vaccines against the covid-19 disease as part of four clinical trials, a senior Chinese government official said on Tuesday, ensuring that no volunteers had “serious adverse effects”.
“Phase 3 clinical trials of the four vaccines [chinesas] are moving forward, ”said Tian Baoguo, deputy director of the Ministry of Science and Technology’s Social Development Department, in 19.
“Adverse effects are common and normal in a potential vaccine. Of the 60,000 people who received the vaccine, some had mild adverse effects, such as swelling in the area where the vaccine was administered or fever, but no serious side effects were reported, ”said the same senior government official.
Phase 3 of clinical trials is the last phase before a vaccine receives approval from regulatory authorities.
China, where the new coronavirus (SARS-Cov-2) was first detected in December 2019, has virtually eradicated the epidemic, with mostly imported cases of infection.
The Chinese Health Commission said on Tuesday that the country had diagnosed 19 cases of covid-19 in the past 24 hours, all from abroad.
Since the beginning of the pandemic, China has registered 85,704 infected and 4634 killed due to covid-19, the disease caused by the new SARS-CoV-2 coronavirus.
The Asian giant is among the countries that have made the most significant advances in research into a potential vaccine against covid-19, which has killed more than 1.1 million people worldwide since the end of December 2019.
Worldwide, and to date, there are more than 40.4 million cases of infection with the new coronavirus.
Several Chinese manufacturers are in the race to produce a vaccine against covid-19, as is the case with the companies Sinovac and Sinopharm.
The two pharmaceutical companies turned to other countries to carry out clinical tests on people, namely Brazil, Indonesia and Turkey.
With the identification in China of few new daily cases of infection, “the conditions were no longer met to conduct a Phase 3 clinical trial” in Chinese territory, clarified Tian Baoguo.
To date, there is no operational vaccine against covid-19, meaning that no vaccine has received approval for large-scale commercial distribution.
However, Chinese authorities are authorizing the emergency use of some of these experimental vaccines.
Since July, in Chinese territory, hundreds of thousands of people working in sectors designated as risky and essential, such as ports or hospitals, have been vaccinated.
By the end of the year, China expects to have the capacity to produce 610 million annual doses of various vaccines against covid-19.
Chinese authorities predict that this annual production will increase to more than 1 billion doses by 2021.